Abstract
Objective: This investigation demonstrates a stability-indicating and reliable “Reverse Phase Ultra-Performance Liquid Chromatography (RP-UPLC)” method to simultaneously quantify Hydrochlorothiazide (HCTZ) and Captopril in the pharmaceutical dosage form.
Methods: Hydrochlorothiazide and Captopril were separated by using C18 column (100 mm x 2.1 mm, 1.7μm) with an isocratic type of elution using mobile phase containing Acetonitrile+0.1% formic acid buffer (60:40), respectively with 0.2 ml/min flow rate. The wavelength used to detected at 210 nm to quantify Hydrochlorothiazide and Captopril.
Results: Captopril and Hydrochlorothiazide peaks were eluted with fine resolution at retention times 0.772 min and 1.679 min, respectively. In 5-30 μg/ml concentration ranges for each Captopril and Hydrochlorothiazide, the calibration graphs were linear, with regression coefficients of 0.9998 and 0.9995, respectively. The suggested Ultra-performance liquid chromatography approach has been shown as sensitive, precise, robust, accurate, specific and stability, indicating through the resolution of Captopril and Hydrochlorothiazide from its degradation-based compounds.
Conclusion: The established ultra-performance liquid chromatography technique was effectively extended to the evaluation of Captopril and Hydrochlorothiazide in the pharmaceutical dosage form, and the test results appeared satisfactory.
Publisher
Innovare Academic Sciences Pvt Ltd